Canine Gastrointestinal Physiology: Motility, Secretion, and Absorption

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Canine gastric emptying, particularly in the fed state, is slower and more variable than in humans, impacting the absorption profiles of orally administered drugs and necessitating careful timing of pharmacologic interventions.
• Small intestinal transit in dogs is faster than in humans, potentially reducing the contact time for absorption of slowly absorbed compounds, a factor critical in pharmacokinetic considerations.
• The canine gastrointestinal tract relies on a complex interplay of neural (enteric nervous system, vagal, sympathetic), hormonal (gastrin, cholecystokinin), and paracrine signals to regulate motility, secretion, digestion, and absorption.
• Gastric acid secretion is continuous basally and increases significantly postprandially, with parietal cells stimulated by histamine, gastrin, and acetylcholine, making the H+/K+ ATPase (proton pump) a key target for pharmacologic intervention.
• Bile acid secretion, stimulated by cholecystokinin in response to luminal fat, is essential for lipid digestion and absorption, with bile salts undergoing significant enterohepatic circulation.
• The gut microbiota plays a significant role in canine gastrointestinal function, fermenting undigested carbohydrates, producing short-chain fatty acids, and modulating motility and secretion through neuroactive compounds.

This article provides a structured review of canine gastrointestinal physiology for veterinary students and practitioners seeking a consolidated reference on normal digestive function. It covers the integrated processes of motility, secretion, digestion, and absorption across the major gastrointestinal segments, with attention to species-specific features that distinguish the dog from other mammals. The content is limited to physiology, gastrointestinal diseases are not addressed.

The canine gastrointestinal tract performs four coordinated functions: propulsion of ingesta, secretion of digestive fluids and enzymes, digestion of macromolecules, and absorption of nutrients, water, and electrolytes. These processes are regulated by overlapping neural, hormonal, and local paracrine signals. Understanding the normal physiology provides the foundation for interpreting clinical signs, selecting diagnostic tests, and predicting the effects of pharmacologic intervention. Comparative aspects are included where they inform clinical reasoning, particularly regarding gastric emptying and intestinal transit, which differ meaningfully between dogs and humans as described in comparative reviews of canine and human gastrointestinal physiology Dressman's comparative review of canine and human GI physiology.

At a Glance

Structural Organization of the Canine Gastrointestinal Tract

The gastrointestinal wall follows a consistent layered plan from esophagus to colon: mucosa, submucosa, muscularis externa, and serosa. The mucosa contains the epithelium, lamina propria, and muscularis mucosae. The submucosa houses the submucosal plexus (Meissner plexus), while the myenteric plexus (Auerbach plexus) lies between the circular and longitudinal muscle layers of the muscularis externa. These plexuses form the enteric nervous system, which can generate coordinated motor patterns independent of central input but remains modulated by vagal and sympathetic efferents.

The canine stomach is a simple, single-chambered organ with a well-developed fundic gland region that secretes acid, pepsinogen, and intrinsic factor. The small intestine is relatively short compared with that of herbivorous species, reflecting the carnivorous diet. The colon is non-sacculated and shorter than in many other species, with a primary role in water conservation instead of extensive fermentation.

Motility: Patterns and Regulation

Fasting Motor Patterns

In the fasted state, the canine gastrointestinal tract exhibits a cyclic pattern of motor activity known as the migrating motor complex (MMC). This cycle has four phases: a quiescent period, a period of irregular contractions, a burst of intense phasic contractions, and a brief transition back to quiescence. The MMC serves as the gastrointestinal housekeeper, sweeping residual ingesta, secretions, and desquamated cells aborally. The cycle length in dogs is approximately 90 to 120 minutes. Disruption of the MMC, as occurs with certain pharmacologic agents or postoperative ileus, permits bacterial overgrowth and retention of luminal contents.

Postprandial Motility

Ingestion of a meal interrupts the MMC and replaces it with a sustained pattern of irregular contractions that mix chyme with digestive secretions and promote gradual gastric emptying. The fed pattern persists until the stomach and proximal small intestine have processed the meal. Gastric emptying of liquids proceeds more rapidly than emptying of solids, which must first be reduced to particles smaller than approximately 1 to 2 mm. The rate of emptying is regulated by duodenal receptors that sense osmolality, pH, and lipid content, generating inhibitory feedback that slows further emptying.

Dogs empty the fed stomach more slowly than humans, while small intestinal transit is faster. These differences have practical consequences for drug absorption, as a slower gastric emptying rate delays delivery of compounds to their primary absorption site, and a faster intestinal transit shortens the residence time available for absorption. The combined effect depends on the physicochemical properties of the drug and the pH dependence of its release characteriztics, as outlined in comparative assessments of canine and human gastrointestinal physiology Dressman's comparative review of canine and human GI physiology.

Colonic Motility

Colonic motility in the dog is characterized by segmental contractions that mix contents and promote water absorption, punctuated by high-amplitude propagating contractions that move feces distally. Defecation is a reflex coordinated by sacral parasympathetic outflow and somatic motor neurons. The canine colon also harbors a dense microbial community that ferments undigested carbohydrates and produces short-chain fatty acids, which serve as an energy source for colonocytes and influence motility through neuroendocrine signaling. The gut microbiota modulates gastrointestinal motility and secretion through the production and consumption of neuroactive compounds, including serotonin, dopamine, and gamma-aminobutyric acid, as reviewed in the microbiota-neurotransmitter literature Strandwitz's review of gut microbiota neurotransmitter modulation.

Secretion

Gastric Secretion

The gastric mucosa secretes hydrochloric acid, pepsinogen, mucus, bicarbonate, and intrinsic factor. Parietal cells produce acid in response to three primary stimuli: histamine from enterochromaffin-like cells, gastrin from G cells, and acetylcholine from vagal efferents. Histamine acts through H2 receptors, gastrin through cholecystokinin-2 receptors, and acetylcholine through M3 muscarinic receptors. These pathways converge on the proton pump, the H+/K+ ATPase, which is the pharmacologic target of proton pump inhibitors.

Pepsinogen is secreted by chief cells and is activated to pepsin by acid in the gastric lumen. Mucus and bicarbonate form a protective gel layer over the surface epithelium. Intrinsic factor, also from parietal cells, is required for cobalamin absorption in the distal ileum. The canine stomach secretes acid continuously in the fasted state, with a marked increase following meal ingestion.

Pancreatic and Biliary Secretion

The exocrine pancreas secretes a bicarbonate-rich fluid and a panel of digestive enzymes, including trypsinogen, chymotrypsinogen, amylase, and lipase. Secretin stimulates bicarbonate secretion in response to duodenal acid, while cholecystokinin stimulates enzyme secretion in response to luminal amino acids and fatty acids. The bile duct and pancreatic duct open into the duodenum at the major duodenal papilla, although the arrangement varies among individual dogs.

Bile is produced by hepatocytes and stored in the gallbladder. Gallbladder contraction is stimulated by cholecystokinin, delivering bile salts into the duodenum where they emulsify lipids and form micelles. Bile salts are largely reabsorbed in the ileum and returned to the liver via the portal circulation, a process known as enterohepatic circulation.

Digestion and Absorption

Carbohydrates

Salivary amylase initiates starch digestion in the oral cavity, although its contribution is limited in dogs. Pancreatic amylase continues this process in the small intestine. The resulting disaccharides are hydrolyzed by brush border enzymes, including maltase, sucrase, and lactase, to monosaccharides. Glucose and galactose are absorbed by sodium-dependent glucose transporter 1, while fructose uses GLUT5. The capacity for disaccharide digestion is generally high in adult dogs, though lactase activity declines after weaning.

Proteins

Protein digestion begins in the stomach with pepsin and continues in the small intestine with pancreatic proteases, including trypsin, chymotrypsin, and carboxypeptidases. The resulting oligopeptides and amino acids are absorbed by multiple brush border and basolateral transporters. Dipeptides and tripeptides are taken up by the proton-coupled oligopeptide transporter 1, while free amino acids use several sodium-dependent and sodium-independent systems.

Lipids

Lipid digestion requires bile salts for emulsification and pancreatic lipase for hydrolysis of triglycerides to monoglycerides and free fatty acids. These products form mixed micelles that deliver lipids to the enterocyte surface. Within the enterocyte, lipids are re-esterified and packaged into chylomicrons, which enter the lymphatic system. Medium-chain triglycerides can be absorbed directly into the portal circulation without chylomicron formation.

Water and Electrolytes

The small intestine absorbs the majority of secreted fluid, with the colon reclaiming most of the remainder. Sodium absorption occurs through multiple mechanisms, including sodium-hydrogen exchange, sodium-glucose cotransport, and electrogenic sodium channels. Chloride follows passively or through chloride-bicarbonate exchange. The renin-angiotensin system influences fluid and electrolyte handling in the gastrointestinal tract, with local components identified throughout the gut wall that modulate absorption and secretion Garg et al. review of the gastrointestinal renin-angiotensin system. Water moves passively in response to osmotic gradients established by solute transport.

Applied Assessment of Canine Gastrointestinal Function

Clinical Evaluation Sequence

The clinical assessment of canine gastrointestinal function proceeds from historical signalment through physical examination, laboratory testing, and, when indicated, advanced diagnostics. The order matters because each step narrows the differential list and determines whether the next, more invasive or costly test is justified.

Historical data should establish the chronicity of signs, the relationship of signs to feeding, stool character and frequency, and the presence of systemic signs such as weight loss or polyphagia. Acute presentations warrant a different diagnostic urgency than chronic, stable signs. Physical examination focuses on body condition, abdominal palpation for pain or organomegaly, rectal examination for perianal or colonic disease, and auscultation for borborygmi, though auscultatory findings correlate poorly with motility disorders.

Laboratory evaluation begins with a minimum database: complete blood count, serum biochemistry, urinalysis, and fecal examination. Fecal flotation and direct smear identify parasitic causes of malabsorption or diarrhea. Serum cobalamin and folate concentrations provide indirect information about ileal and proximal small intestinal function, respectively, though their sensitivity and specificity are limited. Pancreatic lipase immunoreactivity and trypsin-like immunoreactivity assess exocrine pancreatic function when pancreatic disease is suspected.

The decision to pursue advanced diagnostics depends on the response to initial therapy, the persistence of signs, and the presence of alarm features such as hematochezia, marked weight loss, or hypoalbuminemia. Imaging options include abdominal ultrasound, which permits assessment of wall thickness, layering, and motility, and contrast studies, which are now less commonly used. Endoscopy allows direct mucosal inspection and biopsy, but it cannot assess motility directly. Wireless capsule endoscopy and video capsule systems provide imaging of the small intestine but are not widely available in general practice.

Diagnostic Decision Points

The first decision point is whether the presenting signs reflect a disorder of motility, secretion, absorption, or a combination. Vomiting suggests gastric or proximal small intestinal dysfunction. Diarrhea of small bowel origin typically presents with voluminous stools, weight loss, or polyphagia, while large bowel diarrhea presents with increased frequency, tenesmus, and mucus. These distinctions guide the initial diagnostic plan.

The second decision point is whether to treat empirically or to pursue definitive diagnosis. For acute, self-limiting diarrhea in an otherwise stable patient, symptomatic therapy and dietary modification are reasonable. For chronic diarrhea, malabsorption, or weight loss, definitive diagnosis is preferred before committing to long-term therapy. The cost and invasiveness of diagnostics must be weighed against the likelihood that the result will change management.

The third decision point concerns the interpretation of biopsy results. Histopathologic findings in the canine gastrointestinal tract are often nonspecific, and inflammatory infiltrates may be graded but do not always correlate with clinical severity. The clinician must integrate histopathology with clinical signs, laboratory findings, and response to therapy. A normal biopsy does not exclude functional disease, and an abnormal biopsy does not always explain the clinical picture.

Monitoring Parameters and Their Interpretation

Monitoring parameters must be interpreted in the context of the underlying condition. Serum albumin has a long half-life in dogs, so changes lag behind clinical improvement. Cobalamin rechecking is appropriate only after adequate supplementation has been given. Fecal scoring systems are subjective but useful when the same observer performs serial assessments.

Species and Patient Factors That Change the Approach

The canine gastrointestinal tract differs from the human tract in several respects that affect drug absorption and dosage-form performance. Dogs have slower gastric emptying in the fed state, faster small intestinal transit, and higher and more variable intestinal pH compared with humans, as described in a comparative review of canine and human gastrointestinal physiology. These differences matter when extrapolating pharmacokinetic data from human studies to dogs, and they explain why some controlled-release formulations behave differently in dogs.

Patient status changes the diagnostic approach. Puppies with suspected congenital portosystemic shunts require bile acid testing and imaging instead of endoscopic biopsy. Geriatric dogs with weight loss and vomiting warrant screening for neoplasia before pursuing dietary trials. Brachycephalic breeds may have altered gastric motility related to chronic respiratory effort, though the evidence base for this association is limited.

Available equipment changes the correct choice. Practices with ultrasound access can evaluate wall thickness and motility noninvasively. Practices without ultrasound may rely on radiography with barium contrast, which provides limited information about mucosal disease. Endoscopy requires specialized training and equipment, and referral may be appropriate when the clinical suspicion for mucosal disease is high.

The renin-angiotensin system has been identified throughout the gastrointestinal tract and is implicated in the regulation of fluid and electrolyte absorption, motility, and blood flow. Drugs that modify this system are widely available and have excellent safety profiles, but their role in canine gastrointestinal disease management remains investigational. Clinicians should not extrapolate human therapeutic indications to dogs without supporting evidence.

Documentation of Findings

Clinical records should document the diagnostic sequence, the rationale for each test, and the results in a structured format. Serial body weights, fecal scores, and laboratory values should be recorded in a consistent format that permits trend analysis. Imaging findings should describe wall thickness, layering, motility patterns, and any extramural findings. Biopsy reports should be filed with the histopathologic description and the clinical interpretation.

Documentation of dietary trials should include the specific diet, the duration of the trial, the owner's compliance assessment, and the outcome measure used. This information is essential for subsequent management decisions and for communication with referral centers. The gut microbiome modulates gastrointestinal motility, secretion, and epithelial barrier integrity, and the microbial community can be altered by dietary changes, but routine clinical assessment of the microbiome is not yet standardized. Documentation of dietary history is therefore a proxy for microbial assessment in current practice.

Recognized Complications and Failure Modes

Gastrointestinal assessment in the dog can be confounded by several recognized failure modes that mimic primary disease. The most common is the misinterpretation of postprandial hyperlipidaemia as pancreatic disease. Serum triglyceride concentration peaks four to six hours after a fatty meal, and a single elevated reading does not distinguish physiological lipaemia from pancreatitis. The discriminating check is a fasting sample collected after a 12 hour food withdrawal, repeated once to confirm persistence.

Another failure mode is the false-negative fecal flotation in a dog with true parasitism. Intermittent shedding, low worm burden, and flotation solution of inadequate specific gravity all produce negative results. Centrifugation with zinc sulphate at a specific gravity of 1.18 to 1.20 improves sensitivity over passive flotation. If clinical suspicion remains high, repeat sampling on three consecutive days or empirical treatment with recheck examination is appropriate.

The third recognized failure mode is the overinterpretation of isolated hypomotility on abdominal ultrasonography. Intestinal wall thickness and motility vary with the segment examined, the degree of distension, and the patient's stress level. A single static image cannot establish a motility disorder. Real-time assessment over several minutes, combined with the presence or absence of luminal content movement, provides a more reliable basis for judgment.

Early detection of these failures depends on structured re-evaluation. A dog that fails to improve within 48 to 72 hours of symptomatic management warrants repeat examination, not escalation of therapy. The comparison of canine and human gastrointestinal physiology notes that gastric emptying in the fed state is slower in dogs than in humans, so a prolonged postprandial period before reassessment is physiologically expected.

Common Errors in Clinical Reasoning

Less experienced clinicians frequently attribute all diarrhea to dietary indiscretion without considering the distinction between small bowel and large bowel signs. The character of the fecal output, frequency, presence of tenesmus, and evidence of weight loss direct the initial differential list. A dog with hematochezia and tenesmus does not have the same disease probability as one with voluminous steatorrhoeic stools.

A second recurring error is the reflexive use of antimicrobials for acute diarrhea. Most acute episodes are self-limiting and do not require antibacterial therapy. The indiscriminate use of metronidazole or amoxicillin-clavulanate risks disruption of the resident microbiota, which modulates gastrointestinal motility, secretion, and epithelial barrier integrity through multiple pathways including neurotransmitter production gut microbiota effects on host physiology. Antimicrobial therapy is reserved for dogs with fever, hemorrhagic diarrhea with systemic signs, or suspected bacterial translocation.

A third error is the failure to account for drug effects on gastrointestinal function. Corticosteroids, non-steroidal anti-inflammatory drugs, and some antihypertensive agents alter mucosal blood flow, secretion, and permeability. The renin-angiotensin system in gastrointestinal tissues regulates fluid and electrolyte absorption, and drugs that modify this pathway can produce diarrhea or constipation as an expected effect. Reviewing the complete medication list before attributing signs to primary gastrointestinal disease is mandatory.

The corrective action for each error is the same: return to first principles. Recheck the history, re-examine the patient, and ask whether the current diagnosis explains all findings. If it does not, the diagnosis is wrong until proven otherwise.

Limitations of Current Evidence

The evidence base for canine gastrointestinal physiology carries several limitations. Much of the comparative data derives from studies designed for pharmaceutical development instead of clinical investigation. The review comparing canine and human gastrointestinal physiology was written to predict drug absorption, and its motility and pH data, while useful, were not collected to define clinical reference intervals.

Regional intestinal permeability in the dog remains incompletely characterized. Direct measurement of permeability in the mid-jejunum to colon is technically difficult, and most data come from indirect methods or extrapolation from other species. The review of intestinal permeability and drug absorption highlights that knowledge of regional permeability is limited even in humans, and the same constraint applies to dogs.

Expert opinion still differs on the clinical significance of the gut microbiome in functional gastrointestinal signs. The review of the gut microbiome in functional gastrointestinal disorders describes a shift from association studies toward mechanistic investigation, but the therapeutic implications for individual dogs remain uncertain. Fecal microbiome testing is commercially available, yet interpretation standards are not universally agreed, and treatment recommendations based on such testing are not consistently supported by outcome data.

Referral and Escalation Criteria

Referral to a specialist is warranted when the diagnostic plan exceeds the resources or expertise of the primary care setting. Specific indications include suspected protein-losing enteropathy requiring endoscopy and biopsy, suspected exocrine pancreatic insufficiency that does not respond to enzyme replacement, unexplained weight loss despite a negative initial workup, and suspected gastrointestinal neoplasia.

Specialist consultation is also appropriate when a dog fails to respond to two sequential evidence-based treatment trials for a presumed diagnosis. Repeated failure of therapy indicates either an incorrect diagnosis, an unusual disease, or a compliance problem, and each possibility requires a fresh evaluation instead of a third empirical trial.

Laboratory involvement beyond routine biochemistry is indicated for specific questions. Serum cobalamin and folate concentrations help localize disease to the ileum or proximal small intestine. Pancreatic lipase immunoreactivity is the preferred test for suspected pancreatitis, and trypsin-like immunoreactivity confirms exocrine pancreatic insufficiency. Each test must be interpreted in the context of the full clinical picture, not as a standalone diagnostic.

Regulatory reporting is rarely required for gastrointestinal disease in dogs. The WOAH terrestrial animal health standards apply to notifiable diseases, and while most canine gastrointestinal conditions are not reportable, clinicians should verify local requirements when a dog presents with hemorrhagic diarrhea and a history of recent travel or kennel exposure. The AVMA practice resources provide guidance on professional obligations, but specific reporting rules vary by jurisdiction and must be confirmed with the relevant authority.

Frequently Asked Questions

How do I interpret delayed gastric emptying when motility-modifying drugs are already on board?

Drug effects on gastric emptying are dose dependent and often confound the clinical picture. Opioids, anticholinergics, and some calcium channel blockers slow emptying, while metoclopramide and cisapride accelerate it. When a patient on these drugs shows delayed emptying, first establish whether the drug effect is expected at the current dose. Compare the timing of the last dose against the observed emptying delay. If the delay exceeds the drug's expected duration of action, pursue mechanical obstruction or inflammatory disease instead of assuming pharmacologic suppression. The comparative review by Dressman notes that fed-state gastric emptying in dogs is slower than in humans, so account for species-specific baselines before attributing delay to drug effect (comparison of canine and human gastrointestinal physiology).

What can I do when scintigraphy or wireless motility capsules are unavailable?

Clinical assessment of motility without advanced imaging relies on serial radiography with barium-impregnated markers or liquid barium meals. Obtain right lateral and ventrodorsal views at timed intervals, typically 30, 60, and 120 minutes after contrast administration. Compare the progression of the contrast column against published normal transit times for dogs. Ultrasound can assess gastric wall thickness and peristaltic frequency in the antrum, though it is operator dependent. When these tools are unavailable, response to a controlled dietary trial and sequential abdominal palpation over several hours provides a crude but useful estimate of emptying. Document the method used and its limitations in the record so serial comparisons remain valid.

How does the approach differ in a brachycephalic versus a dolichocephalic dog?

Brachycephalic dogs have a higher prevalence of aerophagia and hiatal dysfunction, which can alter gastric distension and emptying patterns. The comparative physiology literature indicates that intestinal pH in dogs is higher and more variable than in humans, and this variability may be amplified in breeds with altered gastrointestinal geometry (comparison of canine and human gastrointestinal physiology). When assessing motility in a brachycephalic patient, account for concurrent respiratory effort that increases intra-abdominal pressure. Emptying studies should be interpreted with the understanding that aerophagia may produce artifactual gastric dilation on radiographs. For dolichocephalic breeds, transit times generally align with published canine norms, but individual variation remains substantial.

What monitoring parameters matter most during refeeding after prolonged fasting?

Refeeding after fasting risks refeeding syndrome, though it is less characterized in dogs than in humans. Monitor serum phosphate, potassium, and magnesium within 24 to 48 hours of initiating nutrition. Track body weight daily and stool output, since osmotic diarrhea signals excessive feeding rate. Auscultate for borborygmi and observe for vomiting, which indicates the gastrointestinal tract cannot yet handle the chosen diet. Start with a highly digestible, low-fat diet and advance volume gradually over several days. The gut microbiome shifts during fasting, and reintroduction of substrate alters microbial metabolism and neurotransmitter production, which can transiently affect motility (neurotransmitter modulation by the gut microbiota). Document electrolyte trends and feeding tolerance at each reassessment.

How should I document motility and secretion findings in the medical record?

Record the specific test performed, the timing of measurements relative to feeding and drug administration, and the numeric results. For contrast studies, note the contrast agent, volume, and radiographic views obtained. Describe motility in functional terms, such as "antral contractions present but reduced in frequency," instead of vague phrases like "sluggish." Document any drugs given within the preceding 24 hours, since these directly affect interpretation. Include the client's report of appetite, vomiting frequency, and fecal consistency, and distinguish observed findings from historical reports. This structure allows a subsequent clinician to repeat the assessment under comparable conditions and detect meaningful change.

How do I explain abnormal motility findings to a client without overstating certainty?

Frame the explanation around what the test showed and what it does not prove. State that the test indicates how quickly food moved through the digestive tract on that day, and that this can vary. Explain that a single abnormal result does not confirm a specific disease, and that follow-up testing or a treatment trial may be needed. Use an analogy to a traffic delay, where the slowdown is observed but the cause requires further investigation. Avoid promising that a motility drug will resolve the problem, since response is variable. The gut microbiome influences motility through host-microbe signaling, and dietary change is often part of the management plan, so mention that diet and medications together may improve function (gut microbiome in functional gastrointestinal disorders). Invite questions and provide written instructions for monitoring at home.

Related Clinical & Scientific Guides

• Canine Respiratory System: Anatomy and Physiology
• Comparative Anatomy of the Mammalian Kidney
• Feline Cardiopulmonary Physiology: Heart-Lung Interactions

References and Further Reading

• Comparison of canine and human gastrointestinal physiology.. 1986.
• Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches.. 2019.
• Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract.. 2012.
• Gene expression in the digestive tissues of ruminants and their relationships with feeding and digestive processes.. 2010.
• The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders.. 2019.
• Neurotransmitter modulation by the gut microbiota.. 2018.
• NCBI Bookshelf: Veterinary and Comparative Biomedical Sciences. NCBI Bookshelf.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Respiratory System: Anatomy and Physiology
• Canine Endocrine Physiology: Hypothalamic-Pituitary Axis
• Canine Cardiac Physiology: Electrical Conduction and Arrhythmias
• Canine Neuromuscular Junction Physiology and Disorders
• Equine Hoof Physiology: Growth, Keratinization, and Shock Absorption

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.